The role of Interventional Radiology in primary and metastatic liver disease – a short review of primary methods and therapy approaches


interventional radiology
hepatocellular carcinoma (HCC)
metastatic liver disease

How to Cite

Ciaś, M., & Mruk, B. (2021). The role of Interventional Radiology in primary and metastatic liver disease – a short review of primary methods and therapy approaches. Wiedza Medyczna, 3(2), 15-19.


Primary and metastatic liver tumors are an increasing global health burden. As of 2020 colorectal cancer (CRC), which often presents with hepatic metastasis in the course of the disease was a second leading cause of cancer-related mortality worldwide. This was followed by hepatic cell carcinoma (HCC). Besides systemic therapies and surgical methods, which are not always applicable, many locoregional approaches were developed and are being increasingly implemented in the field of interventional radiology (IR) – both as primary and bridging procedures.

The purpose of this article is to outline and briefly discuss these primary approaches used in IR in liver neoplastic disease.


1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. DOI: 10.3322/caac.21660
2. Kim KM, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016 Oct;36(10):1490-7. DOI: 10.1111/liv.13107.
3. Loffroy R, Estivalet L, Favelier S, Pottecher P, Genson PY, Cercueil JP, Krausé D. Interventional radiology therapies for liver cancer. Hepatoma Res 2016;2:1-9.
4. Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2018 Apr;68(4):783-797. DOI: 10.1016/j.jhep.2017.10.004
5. Deschamps F., Ronot M., Gelli M., Durand-Labrunie J., Tazdait M., Hollebecque A., Dartigues P., Baere T., Tselikas L. (2020). Interventional Radiology for Colorectal Liver Metastases. Current Colorectal Cancer Reports. 16. DOI: 10.1007/s11888-020-00449-0.
6. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. DOI: 10.1002/14651858.CD011650.pub2.
7. Shi J, Sun Q, Wang Y, Jing X, Ding J, Yuan Q, Ren C, Shan S, Wang Y, Du Z. Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. J Gastroenterol Hepatol. 2014;29(7):1500-7. DOI: 10.1111/jgh.12572.
8. Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, Bai W, Dong Z, Lu Y, Zeng Z, Lou M, Wang H, Gao X, Chang X, An L, Qu J, Li J, Yang Y. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015 May;61(5):1579-90. DOI: 10.1002/hep.27548.
9. Li D, Kang J, Golas BJ, Yeung VW, Madoff DC. Minimally invasive local therapies for liver cancer. Cancer Biol Med. 2014 Dec;11(4):217-36. DOI: 10.7497/j.issn.2095-3941.2014.04.001.
10. Diana M, Schiraldi L, Liu YY, Memeo R, Mutter D, Pessaux P, Marescaux J. High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system-current state of the art and future perspectives. Hepatobiliary Surg Nutr. 2016 Aug;5(4):329-44. DOI: 10.21037/hbsn.2015.11.03.
11. Di Costanzo GG, Francica G, Pacella CM. Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives. World J Hepatol. 2014 Oct 27;6(10):704-15. DOI: 10.4254/wjh.v6.i10.704.
12. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F; PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014 Jul 15;111(2):255-64. DOI: 10.1038/bjc.2014.199.
13. Tong AK, Kao YH, Too CW, Chin KF, Ng DC, Chow PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016 Jun;89(1062):20150943. DOI: 10.1259/bjr.20150943.
14. Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One. 2019 May 29;14(5):e0216935. DOI: 10.1371/journal.pone.0216935.
15. Venerito M, Pech M, Canbay A, Donghia R, Guerra V, Chatellier G, Pereira H, Gandhi M, Malfertheiner P, Chow PKH, Vilgrain V, Ricke J, Leandro G. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with 90Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. J Nucl Med. 2020 Dec;61(12):1736-1742. DOI: 10.2967/jnumed.120.242933.
16. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl. 2015 Sep;21(9):1142-52. DOI: 10.1002/lt.24169.
17. Rubinstein MM, Kaubisch A, Kinkhabwala M, Reinus J, Liu Q, Chuy JW. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol. 2017 Dec;8(6):1051-1055. DOI: 10.21037/jgo.2017.08.11.
18. May BJ, Madoff DC. Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol. 2012 Jun;29(2):81-9. DOI: 10.1055/s-0032-1312568.
19. May BJ, Madoff DC. Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol. 2012 Jun;29(2):81-9. DOI: 10.1055/s-0032-1312568. PMID: 23729977; PMCID: PMC3444878.
20. Lahti S, Ludwig JM, Xing M, Sun L, Zeng D, Kim HS. In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study. PLoS One. 2017 Apr 6;12(4):e0174539. DOI: 10.1371/journal.pone.0174539.
21. Sakr OS, Berndt S, Carpentier G, Cuendet M, Jordan O, Borchard G. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology. J Control Release. 2016 Feb 28;224:199-207. DOI: 10.1016/j.jconrel.2016.01.010.
22. Ludwig JM, Xing M, Gai Y, Sun L, Zeng D, Kim HS. Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. Mol Pharm. 2017 Aug 7;14(8):2824-2830. DOI: 10.1021/acs.molpharmaceut.7b00336.
23. Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations - boosting the anticancer immune response. J Immunother Cancer. 2017 Oct 17;5(1):78. DOI: 10.1186/s40425-017-0284-8.
24. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017 Mar;66(3):545-551. DOI: 10.1016/j.jhep.2016.10.029.
25. Rossi S, Ravetta V, Rosa L, Ghittoni G, Viera FT, Garbagnati F, Silini EM, Dionigi P, Calliada F, Quaretti P, Tinelli C. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011 Jan;53(1):136-47. DOI: 10.1002/hep.23965.
26. White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford). 2014 Dec;16(12):1095-101. DOI: 10.1111/hpb.12313.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.



Download data is not yet available.